NCT03271606 is a Phase 1 clinical trial of ERAS in Enhanced Recovery After Surgery, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT03271606?

NCT03271606 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT03271606?

Interventions in NCT03271606: ERAS, Traditional measures.

What condition does NCT03271606 study?

NCT03271606 studies Enhanced Recovery After Surgery.

Is NCT03271606 still recruiting?

NCT03271606 is currently status unknown. Last updated 5 September 2017.

Last reviewed 2017-09-05 · How we verify

NCT03271606

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ERAS in Video-assisted Mediastinal Surgery

Status unknown Phase 1 Last updated 5 September 2017

What this trial tests

Phase 1 trial testing ERAS in Enhanced Recovery After Surgery in 100 participants. Status unknown.

Timeline

23 August 2017

Primary endpoint
23 February 2018

23 February 2018

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	100
Start date	23 August 2017
Primary completion	23 February 2018
Estimated completion	23 February 2018
Sites	1 location across China

Drugs / interventions tested

ERAS
Traditional measures

Conditions studied

Enhanced Recovery After Surgery — all drugs for Enhanced Recovery After Surgery →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 70, any sex, with Enhanced Recovery After Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center, randomized,single blind study to investigate the effectiveness of enhanced recovery regimen (ERAS) in patients undergoing Video-assisted Mediastinal Surgery. And we also going to compare the effectiveness of ERAS with that of traditional regimen in these patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of ERAS

Trials testing the same drug.

NCT07225205 — Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy · NA · recruiting
NCT07081802 — Effect of Acupuncture and Herbal Medicine on Bowel Recovery After Abdominal Surgery · NA · not yet recruiting
NCT07017361 — ERAS Program Implementation for MIPD · NA · not yet recruiting
NCT05914090 — The Application of Enhanced Recovery After Surgery (ERAS) for Cardiovascular Surgery in Adult · NA · unknown
NCT05914103 — The Application of Enhanced Recovery After Surgery (ERAS) for Cardiovascular Surgery in the Correction of Complex Congen · NA · unknown

Other recruiting trials for Enhanced Recovery After Surgery

Currently open trials in the same condition.

NCT06984952 — Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy · NA · recruiting
NCT06920576 — Effects of Esketamine Versus Magnesium Sulfate on Emotional State and Postoperative Pain in Patients Undergoing Nasal En · Phase 1, PHASE2 · active not recruiting
NCT06719492 — Nutrition Education in Spine Surgery · NA · active not recruiting
NCT06457100 — Esmolol Versus Lidocaine on the Quality of Postoperative Recovery in Patients Undergoing Functional Endoscopic Sinus Sur · Phase 1, PHASE2 · active not recruiting
NCT06369194 — POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol · active not recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03271606 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 5 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03271606.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing